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Abstract 
Reactive oxygen species (ROS) have been implicated in the etiology of many human diseases. Antioxidant 
enzymes such as MnSOD protects cells from oxidative stress and generation of ROS. A case control study, with 
aim to evaluate the relationship between MnSOD Ala-9Val polymorphism and breast cancer was carried out. 
The study included 522 subjects, including 255 cases and 267 controls, 12 samples were missing or yielded no 
results. Genotyping of samples were carried out using PCR-RFLP method. We observed that neither of two 
conditions heterozygous (MnSOD Val/Ala) or Variant/(MnSOD Ala/Ala) was significantly associated with 
overall breast cancer risk. The frequencies of Val and Ala allele was almost similar in cases, however, a 
significant association was seen in case of older women (above 45 years of age) (OR =1.98, CI=1.07-3.66, 
P=0.04). 
--------------------------------------------- 
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Also ORs were elevated in case of women using oral contraceptives carrying Val/Ala genotype. (OR=2.20; 
CI=0.54-8.96). In conclusion MnSOD Ala-9Val polymorphism may modify the risk for breast cancer 
development particularly in presence of age above 45years, oral contraceptives, and urban life style. 
Keywords: MnSOD; breast cancer; polymorphism; case control; RFLP; Polymerase chain reaction. 
1. Introduction  
Women all over the world are affected by breast cancer, with an estimated 1.67 million new cases diagnosed in 
the year 2012, it is the most common cause of death among women in both the developed and developing 
countries [1]. India being the largest populous democracy, about 100,000 breast cancer cases are estimated to be 
diagnosed annually [2,3]. Over the past few years, Kashmir has also witnessed huge rush of patients affected 
with cancer, it has been reported that carcinoma of breast continues to be the second most common cancer 
among women and comprised of 14.6% of all female cancers [4]. Despite the common occurrence the exact 
etiology of breast cancer is still unknown [5], however, the lifetime exposure to exo and endogeneous estrogen 
appears to be closely associated to development and progression of disease. Also ROS may also contribute to 
the development of cancer, During normal cellular process Reactive oxygen species (ROS) are generated [6] 
from estrogen metabolism through catechol estrogen redox cycling [7,8].Since ROS generation is continuous 
process and low level of DNA repair mechanism and lack of histone protection to mitochondrial DNA exposes 
it to more oxidative damage [9]. Therefore, damaged mitochondrial DNA may play an important role in breast 
carcinogenesis [10, 11] in order to neutralize the effect of ROS, Superoxide dismutases play a crucial role in the 
detoxification of superoxide radicals (O-) thereby protecting cells from damage induced by free radicals [12] 
and one such enzyme mitochondria manganese super oxide dismutase (MnSOD) provides major defence 
against  damage by ROS, catalyzing their conversion into H2O2 and O2 in mitochondria. It is encoded by single 
gene containing five exons, located on chromosome 6q25.3, synthesized in the cytosol and post 
transcriptionally modified for transport into the mitochondria [13]. A single nucleotide polymorphism, T to C 
substitution results in change of valine to alanine [14] the Ala variant forms α helical structure while val variant 
results in ß sheet conformation. The two forms differ in their transport rate within mitochondrial membrane, the 
Ala variant is easily transported and therefore has high activity inside as compared to val variant. The high 
activity of Ala variant could result in high production and therefore accumulation of ROS [15,16]It was 
observed that MnSOD is elevated in some cancers as compared to normal counters as in gastric esophageal, 
lung and colorectal cancer cells  [17,18,19] While a variety of cancer cells including breast cancer [20,21] 
pancreatic cancer, ovarian cancer  are known to express reduced level of antioxidant enzymes, especially 
MnSOD, when compared with their normal counter parts. 
2. Materials and Methods 
To investigate the associations between genetic factors and breast cancer risk in Kashmiri population a case 
control study was conducted. Since breast cancer is much more common in women than men therefore the 
population of the study specifically included women. The study was reviewed and approved by the ethics 
committee of Sheri kashmir institute of medical sciences (SKIMS) Soura, Srinagar. All women with suspicious 
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breast cancer lump or symptoms of breast cancer are referred to SKIMS for further examination from other 
hospitals. SKIMS being the central and largest hospital in valley with well-equipped regional cancer centre 
(RCC).All the pateints were ascertained from the RCC which operates as referral center and offers treatment 
and follow up of all breast cancer cases, diagnosed in the valley. Blood samples were collected from 522 
subjects, 255 were female breast cancer patients diagnosed between age of 20-80yrs and 267 were control, 
however, 2%of samples either didn’t yield results or were having incomplete information. Eligible control 
group included women who had no history of breast cancer or any other type of malignancy. All the study 
participants both patients and controls were from Kashmir. The participation rate of cases and controls was high 
covering around 98% of eligible cases and controls. In addition to blood samples a risk factors questionnaire 
which included extensive demographic epidemiologic and pathologic data was obtained from each participant 
through standardized interview. Blood samples of the patients and controls were collected into 5ml EDTA 
coated tubes and stored at -20c until use.  
2.1.Genotyping 
Genomic blood was obtained from whole blood, using phenol-chloroform method. Desired region of the 
genome was amplified using primer set (FORWARD 5’TAGACGGTCCCGCGGCGCTGA3’) and 
(5’CCGTAGTCGTAGGGCAGGTCGGGGA3’) that resulted in the amplification of 133bp fragment. PCR was 
carried out in a final volume of 25µl reaction mixture, 50-70ng DNA, 0.5µM Each primer  in 10X PCR buffer 
containing 1.5mM MgCl2 200µM dNTPs (Fermentas) and 1Unit of Taq polymerase (Fermentas) after 
extensively standardizing all the prameters according to following conditions. The amplification started with an 
initial denaturation step at 95°C for 7 mins cycling parameters were 35 cycles of 95°C for 30 secs, annealing at 
66°C for 30secs, extension at 72°C for 30 secs and final extension at 72°C for 7mins.After amplification, 10µl 
of 133bp PCR product was digested with 5Units BsaWI enzyme at 60°C. The Ala allele contains restriction site 
for the restriction enzyme, resulting in 69 and 64 bp. while Val allele remains uncut. All samples were subjected 
to two rounds of restriction digestion.  
3. Results 
Present study included a total of 250 cases and 260 controls Table 1 represents selective general characteristics 
of cases and controls that were included in the present study. Mean age calculated  for cases was 49.5 years and  
that of controls was 45 years Since no significant differences were observed in cases and controls With respect 
to various characteristics (p>0.05), suggesting frequency matching was adequate. 
Table 2 shows the allele and genotypic frequencies of different polymorphic variants among cases and controls 
resulting from SNP in MnSOD gene, the frequencies of Val and Ala alleles were almost same in cases (48.2, 
51.8) and controls (48.8,51.1). among the cases prevalence of Val/Val , Val/Ala and Ala/Ala genotypes were 
(20.8, 54.8,24.4)  while it was (24.23, 49.23, 26.53) among control respectively, compared with MnSOD 
Val/Val genotype ORs for MnSOD val/ala  were( OR: 1.30; CI:0.83-2.01) and for Ala/Ala (OR:1.07;CI:0.64-
1.77). 
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Table 1: General characteristics of a population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Representing genotypic frequency of genotypes and alleles 
Genotype Case n=250 Control =260 χ 2 OR CI P 
Val/Val 52(20.8) 63(24.23) - Referent - - 
Val/Ala 137(54.8) 128(49.23) 1.10 1.30  0.83-2.01 0.30 
Ala/Ala 61 (24.4) 69(26.53) 0.02 1.07 0.64-1.77 0.88 
Val/Ala+Ala/Ala 198(79.2) 197(75.76) 0.67 1.21 0.80-1.84 0.41 
Val 241 (48.2) 254 (48.8) - Referent - - 
Ala 259 (51.8) 266 (51.1) 0.02 1.02 0.80-1.31 0.88 
When we combined the MnSOD (Val/Ala) and Val/Val genotype to compare these with Val/Val genotype (OR: 
Characteristics Case n=250 Control n=260 P 
value 
Age <45years 113 136  
0.13 
>45years 135 124 
Menopausal status 
 
premenopausal 85 112  
0.04 
postmenopausal 165 148 
Family History 
 
No 212 225 0.66 
Yes 38 35 
Use of oral 
contraceptives 
No 225 222  
0.14 
Yes 25 38 
Partiy Nulliparorus 4 6 0.80 
 
parous 246 254 
Marital status Un married 22 26 0.75 
 
married 228 234 
Smoking status Smoker 10 14  
0.60 
Nonsmoker 240 246 
Dwelling Rural 170 156 0.07 
 
 Urban  80  104 
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1.27; CI: 0.80-1.84). We found no association between genotype and breast cancer. Association between breast 
cancer and pautative risk factors by MnSOD genotypes are presented in table 3.there was significant evidence 
that older women (above 45years of age) carrying the genotype Val/Ala were at risk for breast, also ORs were 
elevated in case of women  with Val/Ala genotype who used oral contraceptives and resided in urban areas. 
However, the presence of Ala alleles was not associated with other pautative risk factors for breast cancer such 
as menopausal status, marital status, smoking, parity, family history (Table 3). 
Table3: Representing clinicopathological characteristics and MnSOD Val-9Ala polymorphism with respect to 
breast cancer 
Risk factors Genotype 
Mnsod 
Val/Val 
Mnsod 
Val/Ala 
Mnsod 
Ala/Ala 
Val/Val+Val/Ala 
Menopausal status Pre menopausal  1.0(ref) 
22/33 
1.27(0.64-
2.48) 
44/52 
1.05(0.47-
2.34) 
19/27 
1.20(0.63-2.25) 
63/79 
Postmenopausal 1.0(ref) 
30/30 
1.22(0.67-
2.20) 
93/76 
1.0(0.51-1.94) 
42/42 
1.14(0.65-2.01) 
135/118 
Age  <45Years 1.0(ref) 
25/30 
0.81(0.43-
1.54) 
51/75 
1.43(0.70-
2.92) 
37/31 
0.99(0.54-1.81) 
88/106 
>45years  1.0(ref) 
27/33 
1.98(1.07-
3.66) 
86/53 
0.77(0.35-
1.58) 
24/38 
1.47(0.82-2.63) 
110/91 
Family history No 1.0(ref) 
42/52 
1.32(0.82-
2.14) 
122/114 
1.0(0.57-1.76) 
48/59 
1.21(0.77-1.92) 
170/173 
yes 1.0(ref) 
10/11 
1.18(0.38-
3.62 
15/14 
1.43(0.43-
4.69) 
13/10 
1.28(0.46-3.54) 
28/24 
 
Use of oral 
contraceptives 
No 1.0 (ref) 
47/52 
1.19(0.74-
1.89) 
128/119 
1.08(0.62-
1.89) 
50/51 
1.15(0.74-1.81) 
178/170 
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4. Discussion  
In order to evaluate the possible influence of the MnSOD Ala-9Val polymorphism on breast cancer risk, we 
carried out a case control study of 510 individuals (250 case and 260 controls) furthermore, we investigated 
yes 1.0 
05/11 
2.20(0.54-
8.96) 
09/09 
1.34(0.36-
4.91) 
11/18 
1.63(0.48/5.44) 
20/27 
    Parity Nulliparous 1.0 
01/01 
0.66(0.02-
18.07) 
02/03 
0.50(0.01-
19.58) 
01/02 
0.60(0.02-13.59) 
03/05 
Parous 1.0 
51/62 
1.31(0.84-
2.04) 
135/125 
1.09(0.65-
1.81) 
60/67 
1.23(0.81-1.88) 
195/192 
Marital status Unmarried 1.0 
05/06 
0.80(0.19-
3.35) 
10/15 
1.68(0.32-
8.76) 
07/05 
1.02(0.26-3.94) 
17/20 
Married 1.0 
47/57 
1.36(0.85-
2.16) 
127/113 
1.02(0.60-
1.73) 
54/64 
1.24(0.80-1.92) 
181/177 
Smoking status Never 1.0 
49/58 
1.30(0.82-
2.03) 
133/122 
1.04(0.62-
1.74) 
58/66 
1.20(0.78-1.85) 
191/188 
Ever 1.0 
03/05 
1.11(0.16-
7.51) 
04/06 
1.66(0.19-
14.27) 
03/03 
1.30(0.22-7.38) 
07/09 
Dwelling Rural 1.0 
37/32 
0.91(0.53-
1.60) 
101/95 
0.95(0.47-
1.90) 
32/29 
0.92(0.54-1.58) 
133/124 
 urban 1.0 
15/31 
2.25(1.03-
4.90) 
36/33 
1.50(0.68-
3.27) 
29/40 
1.84(0.91-3.71) 
65/73 
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whether pautative risk factors influence breast cancer development. MnSOD polymorphic alleles are widely 
variable with ethinicity. The frequency of Ala allele is 12% among Japenese [22] and 14% among Chinese [23] 
where as it is more common in Caucasian population (41.55%). While as in our study, frequency of Ala allele 
was 50% which is comparable to that of Caucasian population. Similar finding was reported by [24] in 
Jordanian population. Our study yielded statistically positive association in case of older women. Also ORs 
were elevated in case women who used oral contraceptives with urban dwelling. These finding are in consistent 
with that reported in Finnish Caucasian population [16] and American population [25]. Previous 
epidemiological studies have shown conflicting. Previous epidemiological studies have shown conflicting 
result, numerous studies as carried by [16,26,27] reported positive association of this SNP with breast cancer 
risk, on the other hand some studies as performed by  [28,25,29] didn’t find any association between MnSOD 
polymorphism and breast cancer risk. These results were similar to those of our study. Futhermore no 
significant modification of ORs for MnSOD Ala/Ala genotype by smoking status was in consistent with the 
results as reported by [30 31], these apparently contradictory results could be analyzed considering biologically 
plausibility and the gene environment and gene gene interactions influence. Some studies reported possible 
gene-gene association such as performed by [32] that described interactions of MnSOD and glutathione 
peroxidase (GPX-I) gene polymorphism associated with breast cancer risk. These results postulate that the 
occurrence of substantial interaction with pro or anti oxidant properties exposures (from environment or genetic 
origin) could interfere in MnSOD polymorphism with breast cancer association. 
5. Conclusion 
In conclusion our study didn’t find any significant association between MnSOD polymorphism and breast 
cancer, however, certain factors like age, oral contraceptives, lifestyle may modify the risk.  Small sample size 
and focusing on only polymorphism were the main limitations of this study. In order to reach any substantive 
results, additional studies of MnSOD polymorphism with larger sample size, which can offer sufficient 
statistical power are needed to further validate the findings and which may help to find out the mechanisms to 
reduce risk of breast cancer, before any strict conclusions can be drawn on this issue. 
Acknowledgments  
The authors would like to express their sincere gratitude to University of Kashmir for providing necessary funds 
and ensuring the conduct of study smoothly. We would like to thank staff of Blood Collection Centre, SKIMS 
for their technical support during sample collection. We also like to thank all the participants in collaborative 
breast cancer study. 
References 
[1] J.Ferlay, I.Soerjomataram, M. Ervik,  R.Dikshit ,S. Eser , C.Mathers , M.Rebelo , D.M.Parkin , D.Forman , 
F.Bray.  “Cancer Incidence and Mortality Worldwide”. IARC Cancer Base No. 11 [Internet]. Lyon, France: 
International Agency for Research on Cancer. GLOBOCAN 2012 v1.0, 2013  Available from 
http://globocan.iarc.fr  
88 
 
International Journal of Sciences: Basic and Applied Research (IJSBAR)(2016) Volume 25, No  1, pp 82-91 
[2] A.Nandakumar, N.Anantha, T.C. Venugopal.“Survivalin breast cancer: a population-based study in 
Bangalore, India.” Int J Cancer, vol. 60, pp. 593-6,1995. 
[3] G.Agarwal, P.V. Pradeep,  V.Aggarwal, C.H. Yip, P.S. Cheung. “Spectrum of breast cancer in Asian 
women.” World J Surg, vol. 31, pp.1031-40,2007. 
[4] M.T.Rasool, M.M. Lone, M.L. Wani, et al. “Cancer in Kashmir, India: burden and pattern of disease.” J Can 
Res Ther, vol.8, pp.243-6,2012. 
[5] B. A. Ponder. “Cancer genetics” Nature, vol. 411, pp.336-341, 2001. 
[6] S. Kathiria, L. D. Butcher, L. A. Feagins, R. F. Souza, C. R. Boland, and A. L. Theiss, “Prohibitin  1 
modulates mitochondrial stress-related autophagy in human colonic epithelial cells,” PLoS One, vol. 7, no. 2, 
Article ID e31231,2012. 
[7] D.Roy, J.G Liehr. “Estrogen, DNA damage and mutation”. Mutat Res, vol.424, pp.107-115,1999. 
[8] Y.Yoshie, H.Ohshima.“Synergistic induction of DNA strand breakage by catechol-estrogen and nitric oxide: 
implications fir hormonal carcinogenesis” Free Radical Biol Med  vol. 24 pp. 341-348, 1998 Ma 
[9] J.S. Penta, F.M. Johnson, J.T. Wachsman, W.C. Copeland. “Mitochondrial DNA in human malignancy.” 
Mutat Res, vol. 488, pp.119-133, 2001 
[10] J.S Penta, F.M. Johnson, J.T.Wachsman, W.C.Copeland.“Mitochondrial DNA in human malignancy” 
Mutat Res, vol. 488 pp.119-133, 2001 
[11] L.R. Cavelli, B.C. Liang. “Mutagenesis, tumorigenicity, and apoptosis: are the mitochondria involved”? 
Mutat Res, vol.398 pp.19-26, 1998  
[12] I. Fridovich, “ Superoxide radical and superoxide dismutase” Annu Rev Biochem, vol.64, pp. 97-112, 1995 
[13] J. R.Wispe, J.C.Clark, M.S.Burnhans, K.E.Kropp, T.R.Kofhagen, and J.Whitsett. A. “Synthesis and 
processing of the precursor for human manganosuperoxide dismutase”. Biochim. Biophys. Acta, vol.994: 
pp.30–36, 1989. 
[14] A.K. Holley, S.K. Dhar, Y. Xu, D.K. St Clair. “Manganese superoxide dismutase: beyond life and death” 
Amino Acids,vol. 42 pp.139-58. 2012. 
[15] A.Sutton, A.Imbert, A.Igoudjil, V.Descatoire S.Cazanave, et al. “The manganese superoxide dismutase 
Ala16Val dimorphism modulates both mitochondrial import and mRNA stability”. Pharmacogenet Genomics, 
vol.15pp.311–319, 2005. 
[16] K .Mitrunen, P.Sillanpaa, V .Kataja,  M .Eskelinen, V.M. Kosma, S.Benhamou, M .Uusitupa, A .Hirvonen. 
89 
 
International Journal of Sciences: Basic and Applied Research (IJSBAR)(2016) Volume 25, No  1, pp 82-91 
“Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk”. 
Carcinogenesis vol. 22 pp.827-829.2001 
[17] R. Izutani, S. Asano, M. Imano, D. Kuroda, M. Kato, and H. Ohyanagi, “Expression of manganese 
superoxide dismutase in esophageal and gastric cancers,” Journal of Gastroenterology, vol.33, no. 6, pp. 816–
822, 1998.  
[18] J.C.M. Ho, S. Zheng, S. A. A. Comhair, C. Farver, and S.C. Erzurum, “Differential expression of 
manganese superoxide dismutase and catalase in lung cancer,” Cancer Research, vol. 61, no. 23, pp. 8578–
8585, 2001.  
[19] Y. Toh, S. Kuninaka, T. Oshiro et al.,  “Overexpression of manganese superoxide dismutase mRNA may 
correlate with aggressiveness in gastric and colorectal adenocarcinomas,”International Journal of Oncology, 
vol. 17,no. 1, pp. 107–112, 2000 
[20] T.C. Chuang, J.Y. Liu, C.-T. Lin et al., “Human manganese superoxide dismutase suppresses HER2/neu-
mediated breast cancer malignancy,” FEBS Letters, vol. 581, no. 23, pp. 4443–4449, 2007. 
[21] Y. Soini, M. Vakkala, K. Kahlos, P. Paakko, and V. Kinnula.“MnSOD expression is less frequent in 
tumour cells of invasive breast carcinomas than in in situ carcinomas or non-neoplastic breast epithelial cells,” 
The Journal of Pathology, vol. 195, no. 2,pp. 156–162, 2001. 
[22] S.Shimoda-Matsubayashi, H. Matsumine, , T. Kobayashi, , Y.Nakagawa-Hattori, Y.Shimizu, , and Y.  
Mizuno. “Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide 
dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a 
study of allelic association in Parkinson’s disease”. Biochem. Biophys. Res. Commun., vol.226,pp. 561–565, 
1996. 
[23] Q. Cai, et al. “Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and 
breast cancer risk: results from the Shanghai Breast Cancer Study”. Breast Cancer Res, vol. 6, n. 6, pp.647-55, 
2004. 
[24] S. Malak Abdel-Fattah, Manar Atoum, Saleem Abdel-Rahman, Ali Alobous. “Genetic Polymorphism of 
Manganese Superoxide Dismutase (MnSOD) Among Breast Cancer and Benign Breast Patients in Jordan: A 
Preliminary Study”. Jordan journal of biological sciences vol.2, pp.77-82. 2009. 
[25] K.M. Egan, P.A. Thompson, L .Titus-Ernstoff, J.H. Moore, C.B. Ambrosone. “MnSOD polymorphism and 
breast cancer in a population based case-control study”. Cancer Lett, vol.199 pp.27-33, 2003. 
[26] M.Bergman, M. Ahnstrom, P. Palmeback Wegman, S.Wingren. “Polymorphism in the mangnese 
superoxide dismutase (MnSOD) gene and risk of  breast cancer in young women”, J.Cancer Res clin. Oncol, 
vol.131, pp. 439-444, 2005. 
90 
 
International Journal of Sciences: Basic and Applied Research (IJSBAR)(2016) Volume 25, No  1, pp 82-91 
[27] C.B. Ambrosone, J.L. Freudenheim, P.A.Thompson, E.Bowman, J.E. Vena, J.R. Marshall, S.Graham, R. 
Laughlin, T.Nemoto, P.G.Shields. “Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary 
antioxidants, and risk of breast cancer”. CancerRes, vol.59, pp. 602-606, 1999. 
[28] R. M. Tamimi, S. E. Hankinson, D.Spiegelman, G. A.Colditz, D. J d Hunter. “Manganese superoxide 
dismutase lymorphism, plasma antioxidants, cigarette smoking, and risk breast cancer”. Cancer Epidemiol 
Biomarkers Prev, vol.13, pp.989-996, 2004. 
[29] R.Millikan, J. Player, A.de Cotret, , P.Moorman, , G.Pittman, V.Vannappagari,  C.K. Tse, and T. Keku. 
“Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based 
case-control study of African Americans and whites”. Breast Cancer Res., vol.6 pp. 264-274, 2004. 
[30] D.G Cox, I. R.M. Tamim, D.J. Hunter, “Gene x gene interaction between MnSOD and GPX-1 and breast 
cancer risk: a nested case-control study”. BMC Cancer, vol. 6,pp. 217-9,2006. 
[31] M. Eras-Erogan E.Akbas, H. Senli, S. Kul, T.Colak, “Relatioship between polymorphism in the manganese 
superoxide dismutase gene and breast cancer”. Mutation Research, vol.680, pp. 7-11, 2009. 
[32] T.E Slanger, J. Chang-Claude, and S.Wang-Gohrke. “Modulation of MnSOD in Cancer: Epidemiological 
and Experimental Evidences 93 Manganese superoxide dismutase Ala-9Val polymorphism, environmental 
modifiers, and risk of breast cancer in a German population”. Cancer Causes Control, vol.17, pp.1025-1031, 
2006. 
91 
 
